Physician profile
Christopher P Ruffini
NPI 1770590424
$10,744.47
in general payments reported to CMS, 2019-2025
36 companies · $2,799 in 2025
The $2,799 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,341 · 2020: $498 · 2021: $836 · 2022: $1,093 · 2023: $1,861 · 2024: $2,318 · 2025: $2,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,961 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,960.91 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,347.40 | 2019-2025 | Skyrizi, Mavyret, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,801.01 | 2019-2025 | Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $975.21 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $766.84 | 2019-2025 | Tremfya, Stelara, Simponi |
| Celgene Corporation | $588.15 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $452.52 | 2024-2025 | Rezdiffra |
| Ardelyx, INC. | $338.90 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $299.96 | 2023-2025 | |
| Lilly USA, LLC | $297.07 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $269.38 | 2019-2024 | Linzess |
| Pfizer INC. | $256.64 | 2019-2025 | |
| Qol Medical, LLC | $235.72 | 2019-2024 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $235.31 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $141.73 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $98.24 | 2019-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $77.66 | 2023-2025 | Uplizna, Avsola, Amjevita |
| Ipsen Biopharmaceuticals, INC | $70.29 | 2024-2025 | Iqirvo, Bylvay |
| Aimmune Therapeutics, INC. | $66.21 | 2023-2025 | Zenpep |
| Merck Sharp & Dohme LLC | $50.71 | 2019-2023 | Dificid |
| Alexion Pharmaceuticals, INC. | $43.05 | 2019 | |
| Intercept Pharmaceuticals, INC. | $41.83 | 2019-2024 | |
| Biofire Diagnostics, LLC | $37.68 | 2019 | |
| Mallinckrodt Hospital Products INC. | $27.85 | 2025 | Terlivaz |
| Redhill Biopharma INC. | $25.53 | 2020-2021 | |
| Allergan, INC. | $24.22 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $19.37 | 2024 | Rapide Balloons |
| Boston Scientific Corporation | $18.98 | 2023 | Watchman Flx |
| Shionogi INC | $17.95 | 2020 | |
| Ferring Pharmaceuticals INC. | $16.50 | 2024 | Rebyota |
| Fresenius Kabi USA, LLC | $16.31 | 2024 | Idacio |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Covidien LP | $16.06 | 2019 | |
| Shire North American Group INC | $14.55 | 2019 | |
| Evoke Pharma, INC. | $14.00 | 2025 | |
| Capsovision, INC. | $13.21 | 2024 | Capsocam Plus |
| Amag Pharmaceuticals, INC. | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ruffini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.